The peptide LDFI (Leu-Asp-Phe-Ile), a selective LEPR antagonist, was developed based on leptin binding site I and demonstrated to inhibit the growth and motility of both ER-positive MCF-7 and ER-negative SKBR3 breast cancer cell lines. Here, LEPR is linked to breast cancer.